About Insulet
Insulet is a company based in Boston (United States) founded in 2000.. Insulet has raised $120.4 million across 8 funding rounds from investors including TIAA, Orbimed and FirstMark. The company has 3,900 employees as of December 31, 2024. Insulet offers products and services including Omnipod. Insulet operates in a competitive market with competitors including Tandem Diabetes, Xeris Pharmaceuticals, Lyra Therapeutics, Valeritas and Credence MedSystems, among others.
- Headquarter Boston, United States
- Employees 3900 as on 31 Dec, 2024
- Stage Public
-
Sectors
HealthcareTechnology
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Insulet Corporation
-
Annual Revenue
$2.07 B22.07as on Dec 31, 2024
-
Net Profit
$418.3 M102.76as on Dec 31, 2024
-
EBITDA
$389.7 M33.09as on Dec 31, 2024
-
Total Equity Funding
$120.4 M (USD)
in 8 rounds
-
Latest Funding Round
$201 M (USD), Post-IPO
Jun 03, 2014
-
Investors
TIAA
& 12 more
-
Employee Count
3900
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Insulet
Insulet is a publicly listed company on the NASDAQ with ticker symbol PODD in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Insulet
Insulet offers a comprehensive portfolio of products and services, including Omnipod. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Tubeless wearable device for continuous insulin delivery to diabetes patients.
Unlock access to complete
Unlock access to complete
Software Development Team
264 people
Senior Team
111 people
Product Management Team
78 people
Leadership Team
65 people
Sales and Marketing
56 people
Operations Team
23 people
Human Resources and Administration
20 people
Data Analysis and Operations Team
20 people
Unlock access to complete
Funding Insights of Insulet
Insulet has successfully raised a total of $120.4M across 8 strategic funding rounds. The most recent funding activity was a Post-IPO round of $201 million completed in June 2014. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 8
- Last Round Post-IPO — $201.0M
-
First Round
First Round
(01 Jun 2000)
- Investors Count 13
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun, 2014 | Amount | Post-IPO - Insulet | Valuation |
investors |
|
| Mar, 2009 | Amount | Debt – Venture - Insulet | Valuation |
investors |
|
| Jan, 2007 | Amount | Series E - Insulet | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Insulet
Insulet has secured backing from 13 investors, including venture fund and institutional investors. Prominent investors backing the company include TIAA, Orbimed and FirstMark. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Healthcare ecosystem is supported through investment and innovation by Deerfield.
|
Founded Year | Domain | Location | |
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Founded Year | Domain | Location | |
|
Venture capital firm focused on healthcare companies
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Insulet
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Insulet
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Insulet Comparisons
Competitors of Insulet
Insulet operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Tandem Diabetes, Xeris Pharmaceuticals, Lyra Therapeutics, Valeritas and Credence MedSystems, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of devices for continuous glucose monitoring and manual insulin delivery
|
|
| domain | founded_year | HQ Location |
Liquid-stable injectables are developed for peptide and protein drug delivery.
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics for ENT diseases are developed.
|
|
| domain | founded_year | HQ Location |
Wearable insulin patch pumps are developed for transdermal delivery.
|
|
| domain | founded_year | HQ Location |
Developer of smart devices for drug delivery
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Insulet
Frequently Asked Questions about Insulet
When was Insulet founded?
Insulet was founded in 2000.
Where is Insulet located?
Insulet is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
Who is the current CEO of Insulet?
Duane DeSisto is the current CEO of Insulet.
Is Insulet a funded company?
Insulet is a funded company, having raised a total of $120.4M across 8 funding rounds to date. The company's 1st funding round was a Series E of $900K, raised on Jun 01, 2000.
How many employees does Insulet have?
As of Dec 31, 2024, the latest employee count at Insulet is 3,900.
What is the annual revenue of Insulet?
Annual revenue of Insulet is $2.07B as on Dec 31, 2024.
What does Insulet do?
Insulet was founded in 2000 and is headquartered in Boston, United States. Operations focus on the medical device sector, where insulin infusion systems for insulin-dependent diabetes are developed, manufactured, and marketed. A key product includes a disposable infusion device with automated cannula insertion, paired with a handheld wireless diabetes manager. This setup supports diabetes management through integrated monitoring and delivery features.
Who are the top competitors of Insulet?
Insulet's top competitors include Tandem Diabetes, Lyra Therapeutics and Xeris Pharmaceuticals.
What products or services does Insulet offer?
Insulet offers Omnipod.
Is Insulet publicly traded?
Yes, Insulet is publicly traded on NASDAQ under the ticker symbol PODD.
Who are Insulet's investors?
Insulet has 13 investors. Key investors include TIAA, Orbimed, FirstMark, Piper Jaffray, and Deerfield.
What is Insulet's ticker symbol?
The ticker symbol of Insulet is PODD on NASDAQ.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.